Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol.

Grimbergen G, Eijkelenkamp H, Snoeren LMW, Bahij R, Bernchou U, van der Bijl E, Heerkens HD, Binda S, Ng SSW, Bouchart C, Paquier Z, Brown K, Khor R, Chuter R, Freear L, Dunlop A, Mitchell RA, Erickson BA, Hall WA, Godoy Scripes P, Tyagi N, de Leon J, Tran C, Oh S, Renz P, Shessel A, Taylor E, Intven MPW, Meijer GJ

Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol.

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Vlahopoulos L, Assenmacher G, Roumeguère T, Peltier A

External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratification.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus
Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis
Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet